The exosome secretion inhibitor neticonazole suppresses intestinal dysbacteriosis-induced tumorigenesis of colorectal cancer
Colorectal cancer (CRC) is the most frequently encountered malignancy associated with the rectum or colon, and accumulating evidences have implicated intestinal dysbacteriosis (IDB, disruption of gut microbiome) and exosomes in the pathology of CRC. We aimed to investigate the effect of IDB on exosome secretion in a CRC xenograft mouse model. An IDB mouse model was established and was inoculated with the CRC cell line SW480 as a xenograft tumor. Tumor growth was monitored for 15 days in sham and IDB mice, after which blood was collected to assess serum exosome secretion. A novel exosome secretion inhibitor, neticonazole, was administered to IDB mice bearing CRC xenograft tumors, followed by monitoring of tumor growth and mouse survival. Western blot analysis was performed in xenograft tumors to investigate the underlying molecular mechanism. IDB promoted CRC xenograft tumor growth and exosome secretion, which could be inhibited by the exosome secretion inhibitor neticonazole. Moreover, neticonazole treatment significantly improved the survival of IDB mice with CRC xenograft tumors, likely through increasing apoptosis of CRC xenograft tumor cells. The exosome secretion inhibitor neticonazole may serve as a promising therapeutic candidate against CRC by suppressing IDB-induced CRC tumorigenesis.
KeywordsIntestinal dysbacteriosis Colorectal cancer Exosome Neticonazole
This study was supported by the National Natural Science Foundation of China (81272720).
Compliance with ethical standards
Conflicts of interest
The authors declare that there are no conflicts of interest.
Research involving human participants and/or animals
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
- 3.Movahedi M, Bishop DT, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L, Bisgaard ML, Dunlop MG, Ho JW, Hodgson SV, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar RS, Side L, Scott RJ, Thomas HJ, Vasen HF, Burn J, Mathers JC (2015) Obesity, aspirin, and risk of colorectal Cancer in carriers of hereditary colorectal Cancer: a prospective investigation in the CAPP2 study. J Clin Oncol 33(31):3591–3597. https://doi.org/10.1200/JCO.2014.58.9952 CrossRefGoogle Scholar
- 6.Van Raay T, Allen-Vercoe E (2017) Microbial interactions and interventions in colorectal Cancer. Microbiol Spectr 5(3). https://doi.org/10.1128/microbiolspec.BAD-0004-2016
- 9.Demory Beckler M, Higginbotham JN, Franklin JL, Ham AJ, Halvey PJ, Imasuen IE, Whitwell C, Li M, Liebler DC, Coffey RJ (2013) Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS. Mol Cell Proteomics 12(2):343–355. https://doi.org/10.1074/mcp.M112.022806 CrossRefGoogle Scholar
- 10.Ji H, Chen M, Greening DW, He W, Rai A, Zhang W, Simpson RJ (2014) Deep sequencing of RNA from three different extracellular vesicle (EV) subtypes released from the human LIM1863 colon cancer cell line uncovers distinct miRNA-enrichment signatures. PLoS One 9(10):e110314. https://doi.org/10.1371/journal.pone.0110314 CrossRefGoogle Scholar
- 11.Bigagli E, Luceri C, Guasti D, Cinci L (2016) Exosomes secreted from human colon cancer cells influence the adhesion of neighboring metastatic cells: role of microRNA-210. Cancer Biol Ther:1–8. https://doi.org/10.1080/15384047.2016.1219815
- 13.Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, Allgayer H (2008) MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 27(15):2128–2136. https://doi.org/10.1038/sj.onc.1210856 CrossRefGoogle Scholar
- 14.Helwa I, Cai J, Drewry MD, Zimmerman A, Dinkins MB, Khaled ML, Seremwe M, Dismuke WM, Bieberich E, Stamer WD, Hamrick MW, Liu Y (2017) A comparative study of serum exosome isolation using differential ultracentrifugation and three commercial reagents. PLoS One 12(1):e0170628. https://doi.org/10.1371/journal.pone.0170628 CrossRefGoogle Scholar
- 17.Datta A, Kim H, McGee L, Johnson AE, Talwar S, Marugan J, Southall N, Hu X, Lal M, Mondal D, Ferrer M, Abdel-Mageed AB (2018) High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: a drug repurposing strategy for advanced cancer. Sci Rep 8(1):8161. https://doi.org/10.1038/s41598-018-26411-7 CrossRefGoogle Scholar
- 20.Chiba M, Kimura M, Asari S (2012) Exosomes secreted from human colorectal cancer cell lines contain mRNAs, microRNAs and natural antisense RNAs, that can transfer into the human hepatoma HepG2 and lung cancer A549 cell lines. Oncol Rep 28(5):1551–1558. https://doi.org/10.3892/or.2012.1967 CrossRefGoogle Scholar
- 22.Huang Z, Feng Y (2017) Exosomes Derived From Hypoxic Colorectal Cancer Cells Promote Angiogenesis Through Wnt4-Induced β-Catenin Signaling in Endothelial Cells. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 25 (5):651–661. https://doi.org/10.3727/096504016X14752792816791
- 26.Huber V, Fais S, Iero M, Lugini L, Canese P, Squarcina P, Zaccheddu A, Colone M, Arancia G, Gentile M, Seregni E, Valenti R, Ballabio G, Belli F, Leo E, Parmiani G, Rivoltini L (2005) Human colorectal Cancer cells induce T-cell death through release of Proapoptotic microvesicles: role in immune escape. Gastroenterology 128(7):1796–1804. https://doi.org/10.1053/j.gastro.2005.03.045 CrossRefGoogle Scholar